Arthneeti

Dr Agarwals Eye Hospital Share Price & Earnings Call Analysis

₹5,269.00-2.63% today
Market cap
₹2,546 Cr
P/E
33.42
ROE
24.22%
PEG
1.51
Price to sales
5.12
Debt to equity
0.94
52W high / low
₹5,759 / ₹4,475
Sales growth (5Y)
27.49%
EBITDA margin
30.48%
Net profit margin
14.30%
Promoter holding
72.67%
Sales (last year)
₹497 Cr

Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Dr Agarwal's Eye rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹921 Cr—
240%+Flat₹575 Cr21.9
3Aster DM Quality Care Ltd20–40%Up 2%+₹59,405 Cr164.6
420–40%Up 2%+₹551 Cr18.5
520–40%Up 0–2%₹1,635 Cr16.5
620–40%Flat₹1.21L Cr57.7

Sign up free to see every company in the sector ranking and track Dr Agarwal's Eye.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Dr Agarwal's Eye announcements

All announcements →

Financials of Dr Agarwal's Eye

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Dr Agarwal's Eye

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +697984768110010295100117118116120
Expenses +48566155566972696880788286
Operating Profit21232321243130263237403434
OPM %30%29%28%27%30%31%29%27%32%32%34%30%28%
Other Income +0011202201132
Interest2222234434422
Depreciation26678109101011111212
Profit before tax18161713171919141923262321
Tax %25%26%24%26%26%25%26%26%14%26%25%26%24%
Net Profit +1412139131414101617191716
EPS in Rs29.1124.5526.7920.0927.2130.0230.1122.1334.0236.7239.9835.7633.60

Financials of Dr Agarwal's Eye

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +118137149153170176140201268319397471
Expenses +103119126129140129109143192227277326
Operating Profit15182324304731597692120145
OPM %13%13%15%16%18%27%22%29%28%29%30%31%
Other Income +0-51223112556
Interest45434977881512
Depreciation699101121192020273946
Profit before tax5-01113172063249627194
Tax %-6%-104%33%49%32%31%125%25%25%26%23%25%
Net Profit +60771214-12437465570
EPS in Rs12.130.0915.6214.4325.3629.11-3.0651.2878.5598.64116.28145.05
Dividend Payout %10%940%10%8%6%0%0%6%4%3%5%0%

Financials of Dr Agarwal's Eye

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital555555555555
Reserves1919253041515073109152205341
Borrowings +27312318246068193232268333326
Other Liabilities +182420283124334244717194
Total Liabilities69797281100141155314390496613766
Fixed Assets +26343336559496214260316393403
CWIP0113000266297128197
Investments00000000001389
Other Assets +434438424547607367838078
Total Assets69797281100141155314390496613766

Financials of Dr Agarwal's Eye

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1417201925393457709094145
Cash from Investing Activity +-10-17-8-11-25-17-11-46-71-70-133-174
Cash from Financing Activity +-5-0-12-82-20-8-40-141725
Net Cash Flow-100-022157-16-22-4
Free Cash Flow311270222310-119-847
CFO/OP106%113%103%98%111%96%120%112%107%112%95%106%

Financials of Dr Agarwal's Eye

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days192416171914231614151314
Inventory Days2382001231481241321179173106117109
Days Payable360371277353292224401410327345263208
Cash Conversion Cycle-103-146-138-189-149-78-260-303-240-224-133-84
Working Capital Days-31-39-25-39-22-34-70-58-50-63-5114
ROCE %19%18%29%32%34%30%11%20%19%18%18%17%
33out of 100

Momentum score · price trend

33 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+3.4%63%
Last 6 months+6.3%64%
Last 3 months+8.1%80%

The price is 22% below its all-time high of ₹6,936.15 (17 Jan 2025). Stocks more than 20% below their peak have their score halved, so 67 became 33.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Dr Agarwal's Eye: 0.4 × 63 + 0.4 × 64 + 0.2 × 80 = 67, halved to 33 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q2 FY27)

    Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves

  • Shalby (Q2 FY27)

    Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S

  • Metropolis Healt (Q2 FY27)

    Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre

  • Nephrocare Health Services (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health